grant
Discovery of Adjuvants for mRNA Vaccines
Organization UNIVERSITY OF CALIFORNIA, SAN DIEGOLocation LA JOLLA, UNITED STATESPosted 30 Sept 2025Deadline 29 Sept 2026
NIHUS FederalResearch GrantFY20252019 novel corona virus2019 novel coronavirus2019-nCoV2019-nCoV vaccineAdjuvantAntigen-Presenting CellsAntigensAssayBioassayBiochemicalBiological AssayCOVID-19 vaccineCOVID-19 virusCOVID19 virusCell BodyCell SurvivalCell ViabilityCellsCoV-2CoV2DoseFormulationGeneticHigh Throughput AssayHumanImmuneImmune Cell ActivationImmunesImmunology procedureIntramuscularLeadLytotoxicityMessenger RNAMiceMice MammalsModelingModern ManMolecularMolecular WeightMurineMusPb elementPreparationProtein BiosynthesisProteinsRNA vaccineRNA-based vaccineRibosomal Peptide BiosynthesisRibosomal Protein BiosynthesisRibosomal Protein SynthesisSARS corona virus 2SARS-CO-V2SARS-COVID-2SARS-CoV-2SARS-CoV-2 vaccineSARS-CoV2SARS-associated corona virus 2SARS-associated coronavirus 2SARS-coronavirus-2SARS-coronavirus-2 vaccineSARS-related corona virus 2SARS-related coronavirus 2SARSCoV2SafetySevere Acute Respiratory Coronavirus 2Severe Acute Respiratory Distress Syndrome CoV 2Severe Acute Respiratory Distress Syndrome Corona Virus 2Severe Acute Respiratory Distress Syndrome Coronavirus 2Severe Acute Respiratory Syndrome CoV 2Severe Acute Respiratory Syndrome CoV 2 vaccineSevere Acute Respiratory Syndrome-associated coronavirus 2Severe Acute Respiratory Syndrome-related coronavirus 2Severe acute respiratory syndrome associated corona virus 2Severe acute respiratory syndrome coronavirus 2Severe acute respiratory syndrome coronavirus 2 vaccineSevere acute respiratory syndrome related corona virus 2Structure-Activity RelationshipTransfectionWorkWuhan coronavirusaccessory cellanalogchemical structure functioncoronavirus disease 2019 vaccinecoronavirus disease 2019 viruscoronavirus disease-19 vaccinecoronavirus disease-19 viruscytotoxicitydesigndesigninghCoV19heavy metal Pbheavy metal leadhigh throughput screeningimmune activationimmunogenimmunologic assayimmunologic assay/testinnate immune pathwayslipid based nanoparticlelipid nanoparticlemRNAmRNA vaccinemRNA-based vaccinemouse modelmurine modelnCoV vaccinenCoV-19 vaccinenCoV19 vaccinenCoV2novelpre-clinical studypreclinical studypreparationsprotective efficacyprotein synthesisscaffoldscaffoldingscale upstructure function relationshipvaccine against 2019-nCovvaccine against COVID-19vaccine against SARS-CoV-2vaccine against SARS-coronavirus-2vaccine against Severe Acute Respiratory Syndrome CoV 2vaccine against Severe acute respiratory syndrome coronavirus 2vaccine candidates against SARS-CoV-2vaccine for novel coronavirusvaccine formulationvaccines preventing COVIDvaccines to prevent COVID
Full Description
The offeror’s proposed work plan aims to identify, characterize and optimize non-toxic, low
molecular weight agents as adjuvants that a) enhance protein antigen accumulation and release in non-immune and immune cells after
intramuscular administration of mRNA vaccine and b) stimulate innate immune pathway-activation in antigen presenting cells.
Grant Number: 75N93024C00022-P00003-9999-1
NIH Institute/Center: NIH
Principal Investigator: DENNIS CARSON
Sign up free to get the apply link, save to pipeline, and set email alerts.
Sign up free →Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click